ADCs

Oncology

Daiichi Sankyo gears up for five ADC launches in 2026

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.

Oncology

ESMO 2025 in review: A new era in oncology, from AI to next-...

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.

Oncology

oncological practices today, with ESMO branding

5 clinical advances and related implications from ESMO 2025

5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.

Oncology

Advances in breast cancer: What’s new from ESMO 2025

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.

Oncology

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

Sales & Marketing

ASCO unpacked: Signals for optimising healthcare comms

Earlier this month, more than 45,000 oncology stakeholders convened at the American Society of Clinical Oncology (ASCO) congress in Chicago to share, learn, and debate the latest cutting-ed

Daiichi Sankyo gears up for five ADC launches in 2026

ESMO 2025 in review: A new era in oncology, from AI to next-...

5 clinical advances and related implications from ESMO 2025

Advances in breast cancer: What’s new from ESMO 2025

ESMO 2025 commences: ADCs, AI, and Asia

ASCO unpacked: Signals for optimising healthcare comms

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

ADCs

Editor's Picks